1. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 4 (April 2023) Authors: Monk, Bradley J; Tewari, Krishnansu S; Dubot, Coraline; Caceres, M Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yañez, Eduardo; Gümüş, Mahmut; Hurtado de Mendoza, Mivael Olivera; Samouëlian, Vanessa; Castonguay, Vincent; Arkhipov, Alexander; Tekin, Cumhur; Li, Kan; Martin Ng... Journal: Lancet oncology Issue: Volume 24:Issue 4(2023) Page Start: 392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗